MedTrace Logo

Immune Response to Influenza Vaccine in Adults With B-cell Malignancies Treated With Idelalisib

NCT03701438 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 2

Last updated 2020-02-20

No results posted yet for this study

Summary

The primary objective of this study is to assess the immune response to an influenza vaccine in adults with B-cell malignancies who are currently receiving treatment with idelalisib in a Gilead-sponsored study (parent study).

Conditions

Interventions

BIOLOGICAL

Influenza Vaccine

Administered per standard of care using a vaccine licensed and recommended in the site's country

Sponsors & Collaborators

Principal Investigators

  • Gilead Study Director · Gilead Sciences

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-23
Primary Completion
2019-10-09
Completion
2019-10-09

Countries

  • Czechia
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03701438 on ClinicalTrials.gov